Skip to content
Menu

RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.

Read at benzinga.com